Spots Global Cancer Trial Database for A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Official Title: A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Study ID: NCT04626635
Conditions
Study Description
Brief Summary: This study is researching an investigational drug called REGN7075 by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe and tolerable REGN7075 is by itself and in combination with cemiplimab (with or without chemotherapy), and to find out what is the best dose of REGN7075 to be given to patients with advanced solid tumors when combined with cemiplimab (with or without chemotherapy). Another aim of the study is to see how effective REGN7075 by itself, or in combination with cemiplimab (with or without chemotherapy), is at treating cancer patients. The study is also looking at: * Side effects that may be experienced by people taking REGN7075 by itself and in combination with cemiplimab with or without chemotherapy. * How REGN7075 works in the body by itself and in combination with cemiplimab with or without chemotherapy. * How much REGN7075 is present in your blood when given by itself and in combination with cemiplimab with or without chemotherapy. * To see if REGN7075 by itself and in combination with cemiplimab with or without chemotherapy works to treat your cancer by controlling the proliferation of tumor cells to shrink your tumor.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Regents of the University of California, San Francisco (UCSF), San Francisco, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
START Midwest - Cancer & Hematology Centers of Western Michigan, PC, Grand Rapids, Michigan, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Tennessee Oncology Sarah Cannon Research Institute, Nashville, Tennessee, United States
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, , France
Hospital Universitari General de Catalunya, Barcelona, , Spain
Hospital Clinico Universitario-University of Valencia, Valencia, , Spain
Baskent Universitesi, Yuregir, Adana, Turkey
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi, Ankara, , Turkey
Istanbul Medeniyet University Prof.Dr.Suleyman Yalcin Şehir Hospital, Istanbul, , Turkey
Contact Details
Name: Clinical Trial Management
Affiliation: Regeneron Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
